<p>Vera Therapeutics, Inc.（纳斯达克代码：VERA - 获取免费报告）的股票在周一交易前出现了下跌。该股票此前收于 20.95 美元，但开盘价为 20.31 美元。Vera Therapeutics 的股票最后交易价格为 20.62 美元，成交量为 155,891 股。</p>
<p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>几家券商最近对 VERA 进行了评估。Wolfe Research 在周一的研究报告中重申了对 Vera Therapeutics 股票的 “同行表现” 评级。Cantor Fitzgerald 将 Vera Therapeutics 的目标价从 107.00 美元下调至 100.00 美元，并在 5 月 7 日的研究报告中对该股票给予了 “超配” 评级。Wedbush 在 5 月 7 日的报告中将 Vera Therapeutics 的目标价从 34.00 美元下调至 26.00 美元，并对该公司给予了 “中性” 评级。Scotiabank 在 6 月 3 日的研究报告中重新发布了对 Vera Therapeutics 股票的 “跑赢大盘” 评级。最后，HC Wainwright 在 6 月 2 日的研究报告中重申了 “买入” 评级，并将 Vera Therapeutics 的目标价从 75.00 美元上调至 85.00 美元。两位投资分析师对该股票给予了持有评级，七位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，Vera Therapeutics 的平均评级为 “适度买入”，平均目标价为 65.00 美元。</p>
<p><strong>查看我们对 Vera Therapeutics 的最新分析</strong></p>
<h2>Vera Therapeutics 股票下跌 3.2%</h2>
<p>该公司的 50 日简单移动平均线为 22.90 美元，200 日简单移动平均线为 25.50 美元。公司市值为 12.9 亿美元，市盈率为-6.76，贝塔值为 1.17。公司的债务与股本比率为 0.10，流动比率为 27.68，速动比率为 27.68。</p>
<p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）最近在 5 月 8 日宣布了其财报。该公司报告本季度每股收益（EPS）为-0.81 美元，低于分析师的共识预期-0.75 美元，差距为-0.06 美元。在去年同期，该公司每股收益为-0.56 美元。整体来看，卖方分析师预计 Vera Therapeutics, Inc.在当前年度的每股收益为-2.89 美元。</p>
<h2>Vera Therapeutics 的内部买卖</h2>
<p>在相关消息中，董事 Patrick G. Enright 在 6 月 24 日的交易中购买了 40,607 股 Vera Therapeutics 的股票。该股票的平均购买成本为每股 22.35 美元，总价值为 907,566.45 美元。购买后，该董事直接持有该公司 3,596,593 股股票，价值约为 80,383,853.55 美元。此次交易使其持股比例增加了 1.14%。该购买在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。公司内部人士持有公司 16.30% 的股份。</p>
<h2>对 Vera Therapeutics 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该公司的持股。J. Safra Sarasin Holding AG 在第二季度获得了 Vera Therapeutics 的新头寸，价值约为 697,000 美元。Platinum Investment Management Ltd.在第二季度将其在 Vera Therapeutics 的持股增加了 14.7%。Platinum Investment Management Ltd.目前持有 159,751 股该公司的股票，价值为 3,764,000 美元，此前在上个季度又购买了 20,433 股。GC Wealth Management RIA LLC 在第二季度购买了 Vera Therapeutics 的新股份，价值约为 320,000 美元。Perigon Wealth Management LLC 在第二季度获得了 Vera Therapeutics 的新股份，价值约为 245,000 美元。最后，Fifth Third Bancorp 在第二季度购买了 Vera Therapeutics 的新头寸，价值约为 102,000 美元。机构投资者和对冲基金持有公司 99.21% 的股份。</p>
<h2>Vera Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Vera Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发和商业化针对严重免疫疾病患者的治疗方案。其主要产品候选药物是 atacicept，这是一种以皮下注射方式自我给药的融合蛋白，目前正在进行针对免疫球蛋白 A 肾病患者的第三阶段临床试验；以及针对狼疮性肾炎的治疗，目前正在进行第二阶段临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Vera Therapeutics</li>
<li>成长投资：你应该在 2022 年采用这种投资策略吗？</li>
<li>AMD 超越 NVIDIA：背后的原因是什么，能否持续？</li>
<li>Roth IRA 计算器：计算你的潜在回报</li>
<li>策略内部人士买入，而分析师预测大幅上涨</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>3 个令人惊讶的盈利赢家改变他们的市场叙事</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Vera Therapeutics 吗？</h2>
<p>在你考虑 Vera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Vera Therapeutics 并不在名单上。</p>
<p>虽然 Vera Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

VERA

<p>Vera Therapeutics（纳斯达克代码：VERA）股价从 20.95 美元跳空下跌至 20.31 美元，最终收于 20.62 美元，反映出 3.2% 的下跌。分析师们的看法不一，Cantor Fitzgerald 将其目标价从 107 美元下调至 100 美元，而 HC Wainwright 则将目标价从 75 美元上调至 85 美元。该公司报告每股亏损 0.81 美元，未能达到预期。内部人士 Patrick G. Enright 购买了 40,607 股，增加了他的持股比例。机构投资者持有 99.21% 的股份。Vera 专注于严重免疫疾病的治疗，其主要候选药物正在进行临床试验</p>

<p>Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $20.95, but opened at $20.31. Vera Therapeutics shares last traded at $20.62, with a volume of 155,891 shares trading hands.</p>
<div class="lb-trans"><p>Vera Therapeutics, Inc.（纳斯达克代码：VERA - 获取免费报告）的股票在周一交易前出现了下跌。该股票此前收于 20.95 美元，但开盘价为 20.31 美元。Vera Therapeutics 的股票最后交易价格为 20.62 美元，成交量为 155,891 股。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>Several brokerages recently weighed in on VERA. Wolfe Research reaffirmed a &#34;peer perform&#34; rating on shares of Vera Therapeutics in a research note on Monday. Cantor Fitzgerald cut their price objective on Vera Therapeutics from $107.00 to $100.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, May 7th. Wedbush decreased their target price on Vera Therapeutics from $34.00 to $26.00 and set a &#34;neutral&#34; rating for the company in a report on Wednesday, May 7th. Scotiabank reissued an &#34;outperform&#34; rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Vera Therapeutics has an average rating of &#34;Moderate Buy&#34; and an average price target of $65.00.</p>
<div class="lb-trans"><p>几家券商最近对 VERA 进行了评估。Wolfe Research 在周一的研究报告中重申了对 Vera Therapeutics 股票的 “同行表现” 评级。Cantor Fitzgerald 将 Vera Therapeutics 的目标价从 107.00 美元下调至 100.00 美元，并在 5 月 7 日的研究报告中对该股票给予了 “超配” 评级。Wedbush 在 5 月 7 日的报告中将 Vera Therapeutics 的目标价从 34.00 美元下调至 26.00 美元，并对该公司给予了 “中性” 评级。Scotiabank 在 6 月 3 日的研究报告中重新发布了对 Vera Therapeutics 股票的 “跑赢大盘” 评级。最后，HC Wainwright 在 6 月 2 日的研究报告中重申了 “买入” 评级，并将 Vera Therapeutics 的目标价从 75.00 美元上调至 85.00 美元。两位投资分析师对该股票给予了持有评级，七位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，Vera Therapeutics 的平均评级为 “适度买入”，平均目标价为 65.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Vera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Vera Therapeutics 的最新分析</strong></p>
</div><h2>Vera Therapeutics Stock Down 3.2%</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股票下跌 3.2%</h2>
</div><p>The firm's 50 day simple moving average is $22.90 and its 200-day simple moving average is $25.50. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -6.76 and a beta of 1.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 27.68 and a quick ratio of 27.68.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 22.90 美元，200 日简单移动平均线为 25.50 美元。公司市值为 12.9 亿美元，市盈率为-6.76，贝塔值为 1.17。公司的债务与股本比率为 0.10，流动比率为 27.68，速动比率为 27.68。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the business earned ($0.56) earnings per share. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）最近在 5 月 8 日宣布了其财报。该公司报告本季度每股收益（EPS）为-0.81 美元，低于分析师的共识预期-0.75 美元，差距为-0.06 美元。在去年同期，该公司每股收益为-0.56 美元。整体来看，卖方分析师预计 Vera Therapeutics, Inc.在当前年度的每股收益为-2.89 美元。</p>
</div><h2>Insider Buying and Selling at Vera Therapeutics</h2>
<div class="lb-trans"><h2>Vera Therapeutics 的内部买卖</h2>
</div><p>In related news, Director Patrick G. Enright acquired 40,607 shares of Vera Therapeutics stock in a transaction on Tuesday, June 24th. The stock was purchased at an average cost of $22.35 per share, with a total value of $907,566.45. Following the purchase, the director directly owned 3,596,593 shares in the company, valued at approximately $80,383,853.55. The trade was a 1.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Company insiders own 16.30% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Patrick G. Enright 在 6 月 24 日的交易中购买了 40,607 股 Vera Therapeutics 的股票。该股票的平均购买成本为每股 22.35 美元，总价值为 907,566.45 美元。购买后，该董事直接持有该公司 3,596,593 股股票，价值约为 80,383,853.55 美元。此次交易使其持股比例增加了 1.14%。该购买在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。公司内部人士持有公司 16.30% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Vera Therapeutics</h2>
<div class="lb-trans"><h2>对 Vera Therapeutics 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. J. Safra Sarasin Holding AG acquired a new position in Vera Therapeutics during the second quarter worth about $697,000. Platinum Investment Management Ltd. raised its stake in shares of Vera Therapeutics by 14.7% during the 2nd quarter. Platinum Investment Management Ltd. now owns 159,751 shares of the company's stock worth $3,764,000 after buying an additional 20,433 shares during the last quarter. GC Wealth Management RIA LLC purchased a new stake in shares of Vera Therapeutics in the 2nd quarter worth about $320,000. Perigon Wealth Management LLC acquired a new stake in Vera Therapeutics in the 2nd quarter valued at about $245,000. Finally, Fifth Third Bancorp purchased a new position in Vera Therapeutics during the 2nd quarter valued at about $102,000. Institutional investors and hedge funds own 99.21% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该公司的持股。J. Safra Sarasin Holding AG 在第二季度获得了 Vera Therapeutics 的新头寸，价值约为 697,000 美元。Platinum Investment Management Ltd.在第二季度将其在 Vera Therapeutics 的持股增加了 14.7%。Platinum Investment Management Ltd.目前持有 159,751 股该公司的股票，价值为 3,764,000 美元，此前在上个季度又购买了 20,433 股。GC Wealth Management RIA LLC 在第二季度购买了 Vera Therapeutics 的新股份，价值约为 320,000 美元。Perigon Wealth Management LLC 在第二季度获得了 Vera Therapeutics 的新股份，价值约为 245,000 美元。最后，Fifth Third Bancorp 在第二季度购买了 Vera Therapeutics 的新头寸，价值约为 102,000 美元。机构投资者和对冲基金持有公司 99.21% 的股份。</p>
</div><h2>Vera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Vera Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.</p>
<div class="lb-trans"><p>Vera Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发和商业化针对严重免疫疾病患者的治疗方案。其主要产品候选药物是 atacicept，这是一种以皮下注射方式自我给药的融合蛋白，目前正在进行针对免疫球蛋白 A 肾病患者的第三阶段临床试验；以及针对狼疮性肾炎的治疗，目前正在进行第二阶段临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>AMD Outperforming NVIDIA: What’s Behind It and Can It Continue?</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Strategy Insiders Buy In While Analysts Predict Big Upside</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>3 Surprising Earnings Winners Changing Their Market Narrative</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Vera Therapeutics</li>
<li>成长投资：你应该在 2022 年采用这种投资策略吗？</li>
<li>AMD 超越 NVIDIA：背后的原因是什么，能否持续？</li>
<li>Roth IRA 计算器：计算你的潜在回报</li>
<li>策略内部人士买入，而分析师预测大幅上涨</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>3 个令人惊讶的盈利赢家改变他们的市场叙事</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vera Therapeutics 吗？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Vera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Vera Therapeutics 并不在名单上。</p>
</div><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vera Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Vera Therapeutics（NASDAQ:VERA）股价跳空下跌 - 接下来会如何发展？